Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 3
Treatment-assignment count: 0
Stratification count: 0
Drug Development Ahead Of Cdx Context
RET fusion
ovarian cancer · Immune Checkpoint Inhibitor
RET fusion is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 5 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Medium
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT02873962 | https://clinicaltrials.gov/study/NCT03410784 | https://clinicaltrials.gov/study/NCT03012620 | https://clinicaltrials.gov/study/NCT04387227 | https://clinicaltrials.gov/study/NCT02606305